ArticleInternational journal of molecular sciences2022
Combined Therapy Using Human Corneal Stromal Stem Cells and Quiescent Keratocytes to Prevent Corneal Scarring after Injury.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- M1-primed human corneal stromal stem cell-derived exosomes delivering protein-coding transforming growth factor-β3 RNA promote corneal regeneration.Stem cells translational medicine · 2026Article
- The Role of Epigenetics in Corneal Fibrosis.Epigenomes · 2026Review
- Human Corneal Stromal Stem Cell Treatment Reduces Established Opacities in Chronic Corneal Scarring.Cells · 2026Article
- Macrophage Extracellular Vesicles: Therapeutic Strategies for Corneal Fibrosis in Rare Diseases.Biomolecules · 2026Review
- The Genetic and Epigenetic Architecture of Keratoconus: Emerging Pathways and Clinical Implications.Genes · 2026Review
- Current Landscape and Future Prospects of Corneal Regenerative Medicine.Ophthalmology and therapy · 2026Review
- Review
- Prediction of cell states and key transcription factors of the human cornea through integrated single-cell omics analyses.PNAS nexus · 2025Article
- Efficient Fabrication of Human Corneal Stromal Cell Spheroids and Promoting Cell Stemness Based on 3D-Printed Derived PDMS Microwell Platform.Biomolecules · 2025Article
- Ultrastructural Aspects of Corneal Functional Recovery in Rats Following Intrastromal Keratocyte Injection.Investigative ophthalmology & visual science · 2025Article
- Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025Review
- Isolation, Culture, and Quality Assessment of Clinical-Grade Corneal Stromal Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A Full Good Manufacturing Practice-Compliant Protocol for Corneal Stromal Stem Cell Cultivation.Bio-protocol · 2024Article
- Review
- Reversed Corneal Fibroblasts Therapy Restores Transparency of Mouse Cornea after Injury.International journal of molecular sciences · 2024Article
- Impact of keratocyte differentiation on corneal opacity resolution and visual function recovery in male rats.Nature communications · 2024Article
- Regenerative Therapy for Corneal Scarring Disorders.Biomedicines · 2024Review
- Good manufacturing practice production of human corneal limbus-derived stromal stem cells and in vitro quality screening for therapeutic inhibition of corneal scarring.Stem cell research & therapy · 2024Article
- Posterior corneoscleral limbus: Architecture, stem cells, and clinical implications.Progress in retinal and eye research · 2023Review
- Ocular injury progression and cornea histopathology from chloropicrin vapor exposure: Relevant clinical biomarkers in mice.Experimental eye research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Corneal blindness due to scarring is conventionally treated by corneal transplantation, but the shortage of donor materials has been a major issue affecting the global success of treatment. Pre-clinical and clinical studies have shown that cell-based therapies using either corneal stromal stem cells (CSSC) or corneal stromal keratocytes (CSK) suppress corneal scarring at lower levels. Further treatments or strategies are required to improve the treatment efficacy. This study examined a combined cell-based treatment using CSSC and CSK in a mouse model of anterior stromal injury. We hypothesize that the immuno-regulatory nature of CSSC is effective to control tissue inflammation and delay the onset of fibrosis, and a subsequent intrastromal CSK treatment deposited collagens and stromal specific proteoglycans to recover a native stromal matrix. Using optimized cell doses, our results showed that the effect of CSSC treatment for suppressing corneal opacities was augmented by an additional intrastromal CSK injection, resulting in better corneal clarity. These in vivo effects were substantiated by a further downregulated expression of stromal fibrosis genes and the restoration of stromal fibrillar organization and regularity. Hence, a combined treatment of CSSC and CSK could achieve a higher clinical efficacy and restore corneal transparency, when compared to a single CSSC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.